Examining the Role of Retrobulbar Hyaluronidase in Reversing Filler-Induced Blindness: A Systematic Review.

Autor:	Paap MK; University of California, San Diego School of Medicine, La Jolla, California, U.S.A., Milman T; Department of Pathology, Wills Eye Hospital and Thomas Jefferson University Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, U.S.A., Ugradar S; Division of Oculoplastics, Jules Stein Eye Institute, University of California, Los Angeles School of Medicine, Los Angeles, California, U.S.A., Goldberg R; Division of Oculoplastics, Jules Stein Eye Institute, University of California, Los Angeles School of Medicine, Los Angeles, California, U.S.A., Silkiss RZ; Division of Oculofacial Plastic Surgery, California Pacific Medical Center, San Francisco, California, U.S.A.
Jazyk:	angličtina
Zdroj:	Ophthalmic plastic and reconstructive surgery [Ophthalmic Plast Reconstr Surg] 2020 May/Jun; Vol. 36 (3), pp. 231-238.
DOI:	10.1097/IOP.0000000000001568
Abstrakt:	Purpose: To provide a systematic review of the literature concerning retrobulbar hyaluronidase injections as a treatment for hyaluronic acid gel filler-induced blindness and evaluate the level of evidence for this proposed therapy. Methods: The authors performed a search of English language articles published on the use of retrobulbar hyaluronidase to reverse vision loss precipitated by hyaluronic acid gel fillers. Articles reviewed included case reports/series, experimental investigations, expert opinion commentaries, and major reviews. To date, there have been no case-control, cohort, or randomized control studies to evaluate this treatment. Five anecdotal descriptions of hyaluronic acid gel filler blindness treated specifically with retrobulbar hyaluronidase were identified, for a total of 9 patients. One hundred twelve articles in total on this treatment and related topics, including filler-induced blindness and alternative treatments, were identified and reviewed. Results: Of the 9 documented cases of patients treated with retrobulbar hyaluronidase for hyaluronic acid-induced blindness, visual improvement was demonstrated in 2 cases. The successes, however, are undermined by inconsistent pretreatment ophthalmic assessment and documentation. Animal studies demonstrate mixed results. Laboratory studies document the inability of hyaluronidase to cross the optic nerve sheath. Conclusions: There is not currently enough evidence to support retrobulbar hyaluronidase as a treatment for filler-induced blindness. Additional studies are needed to further evaluate its efficacy and explore alternative treatments.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu